Clinical Trials Directory

Trials / Completed

CompletedNCT03616418

Ankle Brachial Index Combined With Serum Uric Acid Levels Improve Prediction All Cause Mortality and Cardiovascular Mortality in the Elderly Chinese Population

Status
Completed
Phase
Study type
Observational
Enrollment
3,026 (actual)
Sponsor
Shanghai 10th People's Hospital · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

Peripheral arterial disease (PAD) is a common clinical manifestation of the systemic atherosclerotic process, and the ankle brachial index (ABI) is an ideal tool to diagnose PAD. The association between high serum uric acid levels (SUA) and arterial stiffness as well as endothelial dysfunction has been demonstrated in humans and uric acid has been suggested to be an important modulator of the inflammatory process. It has also been confirmed by clinical studies. Currently, there have been few long term follow up studies focused on the whether serum uric acid levels combined with ankle brachial index can improve prediction all cause mortality and cardiovascular mortality,especially in China population.Therefore, the aim of this study was to elucidate whether ABIcombined with SUA can improve prediction all cause mortality and cardiovascular mortality in the elderly China population independently of the traditional Framingham Risk Score.

Detailed description

This study is a prospective community-based cohort study, which is aimed to investigate the prognostic factors, including conventional cardiovascular risk factors and measure ABI,SUA,asymptomatic target organ damage, for mortality and cardiovascular diseases. All population were separated into ABI ≤0.50,0.51 \<ABI ≤0.9,and 0.91 \<ABI≤1.40 three groups according to the ABI. ABI ≤0.9 was selected as cut point for the definition of PAD. Factors related to CVD and all-cause mortality, major adverse cardiac events (MACE) during follow-up was observed by multivariate Cox regression analysis and log rank test. Potential confounding variables with P \<0.10 were adjusted for multivariate analysis.

Conditions

Interventions

TypeNameDescription
DRUGantiplatelet drugs;statins;antihypertensive drugs

Timeline

Start date
2017-01-01
Primary completion
2019-08-01
Completion
2021-08-01
First posted
2018-08-06
Last updated
2021-12-29

Source: ClinicalTrials.gov record NCT03616418. Inclusion in this directory is not an endorsement.